After being accessible to a select group of users by invitation-only,
Medivizor™, the innovative health information platform, is now available
to the general public (in public beta) with expanded support for medical
conditions including lung, colorectal, breast, and prostate cancer, as
well as melanoma, diabetes, coronary artery disease, hypertension and
stroke.
Individuals coping with a serious illness, as well as their families,
are often confused about the nature of their illness and its treatment.
Those interested in learning more about the diagnosis, prognosis and
recommended treatment turn to websites (e.g., “Dr. Google”) to find the
answers. While the web contains a vast amount of information, this
information is, unfortunately, too general, too technical, sometimes
outdated or misleading, and more often than not irrelevant for the
particular condition of the patient.
Medivizor is a free subscription service to patients and caregivers.
Users of Medivizor receive via email, in a comprehensive and easy to
understand language, updated and relevant information about cutting-edge
research, treatment options, guidelines, clinical trials, and more,
related to their specific condition. This information is personalized
and tailor-made to the particulars of the case and the patient.
Medivizor’s patent-pending technology and team of medical specialists
glean and process published material, including recent research results
and scientific news. Users receive content that’s suitable for the
layman and shareable with their communities and healthcare provider.
Compared to the generic, and overwhelming number of results from keyword
searches on the web, Medivizor saves time and effort.
Medivizor Advances The Patient-Doctor Relationship
Medivizor’s service further helps improve doctor-patient communication
by educating patients about the available treatments and their relative
desirability in an easy to understand format.
The service also assists treating doctors (and their patients) by
alerting them to the most recent research findings and clinical trials
that are relevant to their patient. This is accomplished through
Medivizor’s unique, personalized system for matching individuals with
specific clinical trials available worldwide.
Currently, the new public service applies to more than a quarter of the
133 million Americans with serious or chronic illnesses. In the months
to come, Medivizor will add additional illnesses to its coverage,
eventually supporting all that cope with one or more chronic conditions
to help them, their caregivers, and medical teams.
Leading health and disease-specific bloggers praise Medivizor:
During its closed beta (“early access”) phase, Medivizor gained the
recognition and appreciation of health-related bloggers and thought
leaders who praise the new service it brings to the market.
-
“Step aside, Dr. Google. Enter Medivizor!” wrote early access user,
Anne Marie Ciccarella, leading patient advocate, empowered patient,
caregiver, and acclaimed blogger at Chemo
Brain Fog.
-
“Generic no more…” wrote Fard Johnmar of DigitalHealthPlus,
adding “Medivizor illustrates how organizations delivering
personalized health content will win the future.”
-
“Reliable, Relevant Cancer Info Delivered Straight to Your Inbox,”
stated Huffington
Post, Blogger and Cancer Matchmaker, Robyn Stoller.
Medivizor Aligns With Cancer Related Non-Profit Organizations
Recently, leading cancer related organizations, including the Colon
Cancer Coalition and Chris
4 Life, have partnered with Medivizor to promote its personalized
content platform. “Promoting a product or service is not something we
normally do, but we thought this service was too cool not tell our
community about,” said the Colon Cancer Coalition in a public call to
its members and followers. Medivizor is in the process of collaborating
with other patient organizations as it expands its reach and coverage of
additional illnesses.
About Medivizor
Medivizor
offers a patent-pending, personalized health information platform for
individuals with serious or chronic illnesses. Users of Medivizor are
benefiting from custom content, cutting-edge research, clear and
authoritative descriptions of treatment options, individual-matched
clinical trials, social engagement, and much more. Professor Steven
Kaplan, M.D., Chief Medical Officer, and Chief of the Institute of
Bladder and Prostate Health at Weill Cornell Medical College and
co-founder of MediData Solutions (NASDAQ: MDSL), Dr. Oren Fuerst,
Executive Chairman, a medtech entrepreneur and investor and Tal Givoly,
CEO, former Chief Scientist of Amdocs (NYSE: DOX) founded Medivizor.
Medivizor is at the forefront of the consumer digital health and
empowered / engaged patient movement. Several health and medical blogs
such as ePatient
Dave, MedCityNews,
DiabetesMine,
CancerHawk,
and DigitalHealthPlus
have covered Medivizor through its development phase. Medivizor
recently presented at Digital
Health Summit, #140You,
and CE
Week in New York.
Medivizor is a trademark of Medivizor International Limited
All trademarks are the property of their respective owners
Copyright Business Wire 2013